Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

HYPofractionated Adjuvant RadioTherapy in 1 Versus 2 Weeks in High-risk Patients With Breast Cancer (HYPART): A Non-inferiority, Open-label, Phase III Randomized Trial.

NCT04472845 is registered in ClinicalTrials.gov with Post Graduate Institute of Medical Education and Research, Chandigarh as lead sponsor.

NCT NCT04472845
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04472845 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
HYPofractionated Adjuvant RadioTherapy in 1 Versus 2 Weeks in High-risk Patients With Breast Cancer (HYPART): A Non-inferiority, Open-label, Phase III Randomized Trial.
Lead sponsor
Post Graduate Institute of Medical Education and Research, Chandigarh
Phase
Not applicable
Overall status
Recruiting
Start date
March 30, 2021
Completion date
August 20, 2028
Enrollment
1,018 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, hypofractionation, radiotherapy side effect